Skin Cell Studies

March 14, 2016

Brickell Biotech released results of a phase IIb study of BBI-4000 (sofpironium bromide) for the topical treatment of primary axillary hyperhidrosis. The multicenter, randomized, double blind, placebo-controlled study three concentrations of BBI-4000 versus vehicle (placebo gel) in 189 people with primary axillary hyperhidrosis. Study participants were randomized to apply either 5%, 10% or 15% of BBI-4000 or placebo gel to their underarms once daily for 28 days. At baseline, all subjects had Hyperhidrosis Disease Severity Scale (HDSS) scores of 3 or 4 (scale, 1-4) and =50mg/5min sweat per axilla (underarm). Results showed BBI-4000 met its primary endpoint (ITT analysis) by successfully achieving a statistically significant 2-grade improvement in the HDSS, in a dose-related fashion. At the maximum dose (15%), 38.3% of participants improved more than 2 points on HDSS at day 29 versus 12.2% with vehicle (p<0.01). Additionally, BBI-4000 achieved a statistically significant 1- and 2-grade improvement in a newly developed patient reported outcome measure, the Hyperhidrosis Disease Severity Measure Axillary (HDSM-Ax). Using this measure (ITT analysis), 44.7% achieved a greater than 2-point improvement at day 29 in the 15% treatment group versus 19.5% for vehicle (p=0.01), while 72.3% for the 15% treatment group versus 43.9% vehicle achieved a greater than 1-point improvement (p=0.01). BBI-4000 was well-tolerated at all three concentrations studied. 

September 8, 2014

BioSpecifics Technologies released results of a phase IIa study of XIAFLEX (collagenase clostridium histolyticum or CCH) for the potential treatment of cellulite, or edematous fibrosclerotic panniculopathy. The phase IIa study enrolled 150 women between the ages of 18 and 45 in the U.S. Each subject received up to three treatment sessions of drug or placebo according to randomization: five high-dose 0.84mg, five mid 0.48mg, five low 0.06mg, three placebo. Each treatment session was approximately 21 days apart. Up to 12 injections were administered into cellulite dimples during each session across an entire treatment quadrant: left or right buttock or left or right posterior thigh. Both the mid and high-dose groups of CCH demonstrated a statistically significant improvement in investigators’ assessments of the appearance of cellulite, as measured by Global Aesthetic Improvement Scale (GAIS) scores, with a p-value of <0.05 v. placebo, as well as in patients’ assessments of the appearance of cellulite, as measured by GAIS scores, with a p-value of <0.02 v. placebo. Sixty-eight percent of both the mid and high-dose groups reported being “Satisfied” or “Very Satisfied” with their cellulite treatment, compared to only 34% of placebo patients. Both the mid and high-dose groups of CCH demonstrated a statistically significant improvement in the post-hoc composite responder analysis, as measured by combined investigator and patient GAIS scores, with p-values of 0.021 and 0.004, respectively, v. placebo.

July 8, 2013

RXi Pharmaceuticals reported results from a phase I trial of RXI-109 for the treatment of Connective Tissue Growth Factor (CTGF), a protein that causes abnormal scarring when over-expressed in a wound. This study enrolled 15 volunteers with no known predisposition for abnormal scarring. Each subject received a single intradermal injection of RXI-109 in two 2-cm areas of the abdomen. Two areas on the other side of the abdomen were treated with placebo injections. Within 24 hours of treatment, these areas received an incision that was immediately closed again. RXI-109 was given in dose-ascending manner to five cohorts, with doses ranging from 0.5mg/cm to 5mg/cm (or total doses of RXI-109 per volunteer from 2mg to 20mg). There was a statistically significant reduction in the average CTGF protein concentration in the RXI-109 treated sites compared to placebo treated sites (p = 0.02).

August 2, 2004

Isolagen has reported 6-month interim results of their first phase III study of their Isolagen Process, the use of autologous fibroblast cells to fill facial contour deformities. Data from the ongoing study indicate that the treatment appears to be efficacious in alleviating facial contour deformities, with 77% of subjects achieving clinical response at 4 months and 82% achieving response at 6 months. The study has evaluated 146 subjects, 90.5% of whom were female and 91.8% of whom were Caucasian. Isolagen announced that the study would continue for another 6 months, and that they expected regulatory filing by Q1, 2005.

January 7, 2002

Positive phase I results were reported from testing of 5G1.1 in 13 subjects with dermatomyositis. The drug, a humanized monoclonal antibody C5 complement inhibitor in an intravenous injection formulation, appeared to be well tolerated and to improve skin rash. Treatment was given once a week for five weeks, then every two weeks for up to two months. Though safety was the primary study aim, measurements of skin rash and muscle strength were also recorded, showing consistent trends in improvement with drug administration. Few adverse events were observed, and those seen were comparable for treatment and placebo groups. 5G1.1 is being developed by Alexion Pharmaceuticals.

December 10, 2001

Preliminary phase II trial results indicate that Micrologix Biotech's MBI 594AN produced a 32% reduction in total acne lesion counts (inflammatory plus non-inflammatory lesions) compared to a 14% reduction for placebo. The randomized, double-blind trial enrolled 75 acne subjects who received twice-daily dosing with either one of two formulations of MBI 594AN (2.5% and 5%) or the product's alcohol-based vehicle alone. Subjects treated with MBI 594AN showed a 39% reduction in inflammatory acne lesion counts compared with 21% for the placebo group. In terms of non-inflammatory acne, MBI 594AN treated subjects experienced a 25% improvement in lesion reduction, compared to 10% for placebo treated subjects.

Related Medical Areas